MedTrace Logo

Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

NCT05403333 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2022-06-03

No results posted yet for this study

Summary

This is a phase II trial to explore the efficacy and safety of weekly utidelone in HER2-negative inoperable locally advanced or metastatic breast cancer.

Conditions

Interventions

DRUG

utidelone

Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-10
Primary Completion
2023-03-09
Completion
2025-03-09

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05403333 on ClinicalTrials.gov